Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in Breast Cancer Res

Retrieve available abstracts of 424 articles:
HTML format

Single Articles

    April 2021
  1. WU AH, Franke AA, Wilkens LR, Tseng C, et al
    Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study.
    Breast Cancer Res. 2021;23:44.
    PubMed     Abstract available

    March 2021
  2. SANZ-MORENO A, Palomeras S, Pedersen K, Morancho B, et al
    RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Breast Cancer Res. 2021;23:42.
    PubMed     Abstract available

  3. GATTI G, Betts C, Rocha D, Nicola M, et al
    High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
    Breast Cancer Res. 2021;23:40.
    PubMed     Abstract available

  4. YU J, Qin B, Moyer AM, Sinnwell JP, et al
    Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Breast Cancer Res. 2021;23:41.

  5. DEMICHELE A, Cristofanilli M, Brufsky A, Liu X, et al
    Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    Breast Cancer Res. 2021;23:37.
    PubMed     Abstract available

  6. GALARDI F, De Luca F, Biagioni C, Migliaccio I, et al
    Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Breast Cancer Res. 2021;23:38.
    PubMed     Abstract available

  7. WU SY, Sharma S, Wu K, Tyagi A, et al
    Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
    Breast Cancer Res. 2021;23:35.
    PubMed     Abstract available

  8. FIGUEROA JD, Gierach GL, Duggan MA, Fan S, et al
    Risk factors for breast cancer development by tumor characteristics among women with benign breast disease.
    Breast Cancer Res. 2021;23:34.
    PubMed     Abstract available

  9. GRAESER M, Schrading S, Gluz O, Strobel K, et al
    Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
    Breast Cancer Res. 2021;23:36.
    PubMed     Abstract available

  10. MACPHERSON IR, He Y, Palmieri C
    Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
    Breast Cancer Res. 2021;23:33.
    PubMed     Abstract available

  11. DARRIGUES L, Pierga JY, Bernard-Tessier A, Bieche I, et al
    Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Breast Cancer Res. 2021;23:31.
    PubMed     Abstract available

  12. PAIRAWAN S, Zhao M, Yuca E, Annis A, et al
    First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
    Breast Cancer Res. 2021;23:29.
    PubMed     Abstract available

  13. STRINGER-REASOR EM, May JE, Olariu E, Caterinicchia V, et al
    An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    Breast Cancer Res. 2021;23:30.
    PubMed     Abstract available

    February 2021
  14. AINE M, Boyaci C, Hartman J, Hakkinen J, et al
    Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly.
    Breast Cancer Res. 2021;23:28.

  15. STENSTROM J, Hedenfalk I, Hagerling C
    Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Breast Cancer Res. 2021;23:27.
    PubMed     Abstract available

  16. KAMINSKA K, Akrap N, Staaf J, Alves CL, et al
    Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Breast Cancer Res. 2021;23:26.
    PubMed     Abstract available

  17. RAMIN C, Withrow DR, Davis Lynn BC, Gierach GL, et al
    Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Breast Cancer Res. 2021;23:24.
    PubMed     Abstract available

  18. PAL CHOUDHURY P, Brook MN, Hurson AN, Lee A, et al
    Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Breast Cancer Res. 2021;23:22.
    PubMed     Abstract available

  19. MOURON S, Manso L, Caleiras E, Rodriguez-Peralto JL, et al
    FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Breast Cancer Res. 2021;23:21.
    PubMed     Abstract available

  20. AINE M, Boyaci C, Hartman J, Hakkinen J, et al
    Molecular analyses of triple-negative breast cancer in the young and elderly.
    Breast Cancer Res. 2021;23:20.
    PubMed     Abstract available

  21. GILMORE N, Mohile S, Lei L, Culakova E, et al
    The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy.
    Breast Cancer Res. 2021;23:19.
    PubMed     Abstract available

  22. SHANG L, Hattori M, Fleming G, Jaskowiak N, et al
    Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.
    Breast Cancer Res. 2021;23:18.
    PubMed     Abstract available

  23. JOHANSSON ALV, Trewin CB, Fredriksson I, Reinertsen KV, et al
    In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
    Breast Cancer Res. 2021;23:17.
    PubMed     Abstract available

    January 2021
  24. ROHAN TE, Arthur R, Wang Y, Weinmann S, et al
    Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer.
    Breast Cancer Res. 2021;23:15.
    PubMed     Abstract available

  25. ROZENBLIT M, Mun S, Soulos P, Adelson K, et al
    Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Breast Cancer Res. 2021;23:14.
    PubMed     Abstract available

  26. ASPERGER H, Stamm N, Gierke B, Pawlak M, et al
    Correction to: Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
    Breast Cancer Res. 2021;23:13.

  27. CHEN C, Pan Y, Bai L, Chen H, et al
    MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer.
    Breast Cancer Res. 2021;23:12.
    PubMed     Abstract available

  28. JIAO X, Wang M, Zhang Z, Li Z, et al
    Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.
    Breast Cancer Res. 2021;23:11.
    PubMed     Abstract available

  29. ALHENC-GELAS M, Cabel L, Berger F, Delaloge S, et al
    Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
    Breast Cancer Res. 2021;23:9.
    PubMed     Abstract available

  30. SCHMID P, Sablin MP, Bergh J, Im SA, et al
    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
    Breast Cancer Res. 2021;23:8.
    PubMed     Abstract available

  31. SANCHEZ K, Kim I, Chun B, Pucilowska J, et al
    Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
    Breast Cancer Res. 2021;23:2.
    PubMed     Abstract available

  32. LIAO YM, Wang YH, Hung JT, Lin YJ, et al
    High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Breast Cancer Res. 2021;23:5.
    PubMed     Abstract available

  33. HOWARTH KD, Mirza T, Cooke SL, Chin SF, et al
    NRG1 fusions in breast cancer.
    Breast Cancer Res. 2021;23:3.
    PubMed     Abstract available

  34. SOBOTTKA B, Moch H, Varga Z
    Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer.
    Breast Cancer Res. 2021;23:4.
    PubMed     Abstract available

  35. PRIEDIGKEIT N, Ding K, Horne W, Kolls JK, et al
    Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
    Breast Cancer Res. 2021;23:1.
    PubMed     Abstract available

    December 2020
  36. LUNDGREN C, Bendahl PO, Ekholm M, Ferno M, et al
    Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Breast Cancer Res. 2020;22:140.
    PubMed     Abstract available

  37. SEREESONGSAENG N, McDowell SH, Burrows JF, Scott CJ, et al
    Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.
    Breast Cancer Res. 2020;22:139.
    PubMed     Abstract available

  38. WATT GP, Sung J, Morris EA, Buys SS, et al
    Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    Breast Cancer Res. 2020;22:138.
    PubMed     Abstract available

  39. ALHAREERI AA, Archer KJ, Fu H, Lyon DE, et al
    Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study.
    Breast Cancer Res. 2020;22:137.
    PubMed     Abstract available

  40. WAFAI R, Williams ED, de Souza E, Simpson PT, et al
    Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer-insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system.
    Breast Cancer Res. 2020;22:136.
    PubMed     Abstract available

  41. GHALEB A, Padellan M, Marchenko N
    Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Breast Cancer Res. 2020;22:133.
    PubMed     Abstract available

  42. FERNANDEZ SV, MacFarlane AW 4th, Jillab M, Arisi MF, et al
    Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Breast Cancer Res. 2020;22:134.
    PubMed     Abstract available

  43. FREDOLINI C, Pathak KV, Paris L, Chapple KM, et al
    Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
    Breast Cancer Res. 2020;22:135.
    PubMed     Abstract available

    November 2020
  44. LEONE JP, Emblem KE, Weitz M, Gelman RS, et al
    Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
    Breast Cancer Res. 2020;22:131.
    PubMed     Abstract available

  45. ZOELLER JJ, Vagodny A, Daniels VW, Taneja K, et al
    Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Breast Cancer Res. 2020;22:132.
    PubMed     Abstract available

  46. LEE KM, Lee H, Han D, Moon WK, et al
    Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.
    Breast Cancer Res. 2020;22:130.
    PubMed     Abstract available

  47. WANG SM, Pfeiffer RM, Gierach GL, Falk RT, et al
    Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
    Breast Cancer Res. 2020;22:129.
    PubMed     Abstract available

  48. JORDAN KR, Hall JK, Schedin T, Borakove M, et al
    Extracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach.
    Breast Cancer Res. 2020;22:128.
    PubMed     Abstract available

  49. BHATTARAI S, Saini G, Gogineni K, Aneja R, et al
    Quadruple-negative breast cancer: novel implications for a new disease.
    Breast Cancer Res. 2020;22:127.
    PubMed     Abstract available

  50. GIANNOUDIS A, Malki MI, Rudraraju B, Mohhamed H, et al
    Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Breast Cancer Res. 2020;22:126.
    PubMed     Abstract available

  51. BALCIOGLU O, Heinz RE, Freeman DW, Gates BL, et al
    CRIPTO antagonist ALK4(L75A)-Fc inhibits breast cancer cell plasticity and adaptation to stress.
    Breast Cancer Res. 2020;22:125.
    PubMed     Abstract available

  52. QUINTELA-FANDINO M, Holgado E, Manso L, Morales S, et al
    Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
    Breast Cancer Res. 2020;22:124.
    PubMed     Abstract available

  53. KIMBUNG S, Inasu M, Stalhammar T, Nodin B, et al
    CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
    Breast Cancer Res. 2020;22:123.
    PubMed     Abstract available

  54. DOAN TB, Cheung V, Clyne CD, Hilton HN, et al
    A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer.
    Breast Cancer Res. 2020;22:122.
    PubMed     Abstract available

  55. REDDY TP, Rosato RR, Li X, Moulder S, et al
    A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
    Breast Cancer Res. 2020;22:121.
    PubMed     Abstract available

  56. GARRIDO-CASTRO AC, Saura C, Barroso-Sousa R, Guo H, et al
    Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Breast Cancer Res. 2020;22:120.
    PubMed     Abstract available

    October 2020
  57. HAN S, Choi JY
    Prognostic value of (18)F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2020;22:119.
    PubMed     Abstract available

  58. CAIRAT M, Al Rahmoun M, Gunter MJ, Severi G, et al
    Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women.
    Breast Cancer Res. 2020;22:118.
    PubMed     Abstract available

  59. FRANCESCANGELI F, De Angelis ML, Zeuner A
    COVID-19: a potential driver of immune-mediated breast cancer recurrence?
    Breast Cancer Res. 2020;22:117.
    PubMed     Abstract available

  60. AQBI HF, Coleman C, Zarei M, Manjili SH, et al
    Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
    Breast Cancer Res. 2020;22:116.
    PubMed     Abstract available

  61. DI COSIMO S, Porcu L, Agbor-Tarh D, Cinieri S, et al
    Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
    Breast Cancer Res. 2020;22:115.
    PubMed     Abstract available

  62. HENG B, Bilgin AA, Lovejoy DB, Tan VX, et al
    Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.
    Breast Cancer Res. 2020;22:113.
    PubMed     Abstract available

  63. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
    Pubertal timing and breast cancer risk in the Sister Study cohort.
    Breast Cancer Res. 2020;22:112.
    PubMed     Abstract available

  64. O'SHAUGHNESSY J, Brezden-Masley C, Cazzaniga M, Dalvi T, et al
    Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    Breast Cancer Res. 2020;22:114.
    PubMed     Abstract available

  65. DE GREGORIO A, Haberle L, Fasching PA, Muller V, et al
    Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
    Breast Cancer Res. 2020;22:111.
    PubMed     Abstract available

  66. MONSON KR, Goldberg M, Wu HC, Santella RM, et al
    Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    Breast Cancer Res. 2020;22:109.
    PubMed     Abstract available

  67. DRUCKER A, Yoo BH, Khan IA, Choi D, et al
    Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Breast Cancer Res. 2020;22:110.
    PubMed     Abstract available

  68. TUAZON AMA, Lott P, Bohorquez M, Benavides J, et al
    Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
    Breast Cancer Res. 2020;22:108.
    PubMed     Abstract available

  69. FUMAGALLI C, Ranghiero A, Gandini S, Corso F, et al
    Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Breast Cancer Res. 2020;22:107.
    PubMed     Abstract available

  70. FALSTIE-JENSEN AM, Esen BO, Kjaersgaard A, Lorenzen EL, et al
    Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study.
    Breast Cancer Res. 2020;22:106.
    PubMed     Abstract available

  71. DURCKER A, Yoo BH, Khan IA, Choi D, et al
    Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Breast Cancer Res. 2020;22:105.
    PubMed     Abstract available

    September 2020
  72. WANG D, Xiao F, Feng Z, Li M, et al
    Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
    Breast Cancer Res. 2020;22:103.
    PubMed     Abstract available

  73. BRENTNALL AR, Warren R, Harkness EF, Astley SM, et al
    Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
    Breast Cancer Res. 2020;22:101.
    PubMed     Abstract available

  74. MORSING M, Kim J, Villadsen R, Goldhammer N, et al
    Fibroblasts direct differentiation of human breast epithelial progenitors.
    Breast Cancer Res. 2020;22:102.
    PubMed     Abstract available

  75. NIEHOFF NM, Keil AP, Jones RR, Fan S, et al
    Outdoor air pollution and terminal duct lobular involution of the normal breast.
    Breast Cancer Res. 2020;22:100.
    PubMed     Abstract available

  76. LEE ARGOV EJ, Acheampong T, Terry MB, Rodriguez CB, et al
    Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.
    Breast Cancer Res. 2020;22:99.
    PubMed     Abstract available

  77. CABEL L, Rosenblum D, Lerebours F, Brain E, et al
    Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast Cancer Res. 2020;22:98.
    PubMed     Abstract available

  78. JAGER A, de Vries EGE, der Houven van Oordt CWM, Neven P, et al
    A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging.
    Breast Cancer Res. 2020;22:97.
    PubMed     Abstract available

  79. BERTRAND KA, Bethea TN, Gerlovin H, Coogan PF, et al
    Aspirin use and risk of breast cancer in African American women.
    Breast Cancer Res. 2020;22:96.
    PubMed     Abstract available

    August 2020
  80. GABRIELSON M, Azam S, Hardell E, Holm M, et al
    Hormonal determinants of mammographic density and density change.
    Breast Cancer Res. 2020;22:95.
    PubMed     Abstract available

  81. LO GULLO R, Daimiel I, Rossi Saccarelli C, Bitencourt A, et al
    MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
    Breast Cancer Res. 2020;22:93.
    PubMed     Abstract available

  82. KLEMENT RJ, Champ CE, Kammerer U, Koebrunner PS, et al
    Impact of a ketogenic diet intervention during radiotherapy on body composition: III-final results of the KETOCOMP study for breast cancer patients.
    Breast Cancer Res. 2020;22:94.
    PubMed     Abstract available

  83. BERNHARDT SM, Dasari P, Wrin J, Raymond W, et al
    Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
    Breast Cancer Res. 2020;22:90.
    PubMed     Abstract available

  84. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2020;22:91.
    PubMed     Abstract available

  85. CHAO X, Liu L, Sun P, Yang X, et al
    Immune parameters associated with survival in metaplastic breast cancer.
    Breast Cancer Res. 2020;22:92.
    PubMed     Abstract available

  86. O'BRIEN NA, McDermott MSJ, Conklin D, Luo T, et al
    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    Breast Cancer Res. 2020;22:89.
    PubMed     Abstract available

  87. DIAZ-SANTANA MV, O'Brien KM, D'Aloisio AA, Regalado G, et al
    Perinatal and postnatal exposures and risk of young-onset breast cancer.
    Breast Cancer Res. 2020;22:88.
    PubMed     Abstract available

  88. NANOU A, Zeune LL, Bidard FC, Pierga JY, et al
    HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Breast Cancer Res. 2020;22:86.
    PubMed     Abstract available

  89. PORTMAN N, Milioli HH, Alexandrou S, Coulson R, et al
    MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Breast Cancer Res. 2020;22:87.
    PubMed     Abstract available

  90. KUROZUMI S, Alsaleem M, Monteiro CJ, Bhardwaj K, et al
    Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Breast Cancer Res. 2020;22:85.
    PubMed     Abstract available

  91. LI L, Lin L, Veeraraghavan J, Hu Y, et al
    Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Breast Cancer Res. 2020;22:84.
    PubMed     Abstract available

  92. BIGANZOLI L, Cinieri S, Berardi R, Pedersini R, et al
    EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
    Breast Cancer Res. 2020;22:83.
    PubMed     Abstract available

    July 2020
  93. KANG T, Yau C, Wong CK, Sanborn JZ, et al
    A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
    Breast Cancer Res. 2020;22:81.
    PubMed     Abstract available

  94. RUUD KF, Hiscox WC, Yu I, Chen RK, et al
    Distinct phenotypes of cancer cells on tissue matrix gel.
    Breast Cancer Res. 2020;22:82.
    PubMed     Abstract available

  95. SINGH M, Zhou X, Chen X, Santos GS, et al
    Identification and targeting of selective vulnerability rendered by tamoxifen resistance.
    Breast Cancer Res. 2020;22:80.
    PubMed     Abstract available

  96. LIPS EH, Benard-Slagter A, Opdam M, Scheerman CE, et al
    BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Breast Cancer Res. 2020;22:79.
    PubMed     Abstract available

  97. MCGEE EE, Kim CH, Wang M, Spiegelman D, et al
    Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study.
    Breast Cancer Res. 2020;22:78.
    PubMed     Abstract available

  98. MADIGAN LI, Dinh P, Graham JD
    Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Breast Cancer Res. 2020;22:77.
    PubMed     Abstract available

  99. BONNEAU C, Elies A, Kieffer Y, Bourachot B, et al
    A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
    Breast Cancer Res. 2020;22:76.
    PubMed     Abstract available

  100. ASPERGER H, Stamm N, Gierke B, Pawlak M, et al
    Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
    Breast Cancer Res. 2020;22:75.
    PubMed     Abstract available

  101. EMAD A, Ray T, Jensen TW, Parat M, et al
    Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
    Breast Cancer Res. 2020;22:74.
    PubMed     Abstract available

    June 2020
  102. TERKELSEN T, Russo F, Gromov P, Haakensen VD, et al
    Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Breast Cancer Res. 2020;22:73.
    PubMed     Abstract available

  103. BYERLY JH, Port ER, Irie HY
    PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Breast Cancer Res. 2020;22:72.
    PubMed     Abstract available

  104. BLOHMER M, Zhu L, Atkinson JM, Beriwal S, et al
    Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
    Breast Cancer Res. 2020;22:70.
    PubMed     Abstract available

  105. FINLAY-SCHULTZ J, Jacobsen BM, Riley D, Paul KV, et al
    New generation breast cancer cell lines developed from patient-derived xenografts.
    Breast Cancer Res. 2020;22:68.
    PubMed     Abstract available

  106. GUO H, Ding Q, Gong Y, Gilcrease MZ, et al
    Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Breast Cancer Res. 2020;22:69.
    PubMed     Abstract available

  107. BERGQVIST M, Elebro K, Sandsveden M, Borgquist S, et al
    Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.
    Breast Cancer Res. 2020;22:67.
    PubMed     Abstract available

  108. ROBERTS MS, Anstine LJ, Finke VS, Bryson BL, et al
    KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Breast Cancer Res. 2020;22:66.
    PubMed     Abstract available

  109. MALINIAK ML, Cheriyan AM, Sherman ME, Liu Y, et al
    Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer.
    Breast Cancer Res. 2020;22:65.
    PubMed     Abstract available

  110. GU X, Wang B, Zhu H, Zhou Y, et al
    Age-associated genes in human mammary gland drive human breast cancer progression.
    Breast Cancer Res. 2020;22:64.
    PubMed     Abstract available

  111. BAKER LA, Holliday H, Roden D, Krisp C, et al
    Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
    Breast Cancer Res. 2020;22:63.
    PubMed     Abstract available

  112. YIN L, Duan JJ, Bian XW, Yu SC, et al
    Triple-negative breast cancer molecular subtyping and treatment progress.
    Breast Cancer Res. 2020;22:61.
    PubMed     Abstract available

  113. ABDOU Y, Attwood K, Cheng TD, Yao S, et al
    Racial differences in CD8(+) T cell infiltration in breast tumors from Black and White women.
    Breast Cancer Res. 2020;22:62.
    PubMed     Abstract available

  114. HUMPHRIES BA, Cutter AC, Buschhaus JM, Chen YC, et al
    Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.
    Breast Cancer Res. 2020;22:60.
    PubMed     Abstract available

  115. PAUL R, Luo M, Mo X, Lu J, et al
    FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
    Breast Cancer Res. 2020;22:59.
    PubMed     Abstract available

    May 2020
  116. ONISHI N, Sadinski M, Hughes MC, Ko ES, et al
    Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.
    Breast Cancer Res. 2020;22:58.
    PubMed     Abstract available

  117. CLATOT F, Perdrix A, Beaussire L, Lequesne J, et al
    Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
    Breast Cancer Res. 2020;22:56.
    PubMed     Abstract available

  118. SUTTON EJ, Onishi N, Fehr DA, Dashevsky BZ, et al
    A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.
    Breast Cancer Res. 2020;22:57.
    PubMed     Abstract available

  119. VUAGNAT P, Frelaut M, Ramtohul T, Basse C, et al
    COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.
    Breast Cancer Res. 2020;22:55.
    PubMed     Abstract available

  120. KIM HJ, Noh WC, Lee ES, Jung YS, et al
    Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
    Breast Cancer Res. 2020;22:54.
    PubMed     Abstract available

  121. CHOOTIPONGCHAIVAT S, van Ravesteyn NT, Li X, Huang H, et al
    Modeling the natural history of ductal carcinoma in situ based on population data.
    Breast Cancer Res. 2020;22:53.
    PubMed     Abstract available

  122. GOLDSTEIN LJ, Perez RP, Yardley D, Han LK, et al
    Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
    Breast Cancer Res. 2020;22:52.
    PubMed     Abstract available

  123. JAYARAMAN S, Hou X, Kuffel MJ, Suman VJ, et al
    Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2020;22:51.
    PubMed     Abstract available

  124. KONAN HP, Kassem L, Omarjee S, Surmieliova-Garnes A, et al
    ERalpha-36 regulates progesterone receptor activity in breast cancer.
    Breast Cancer Res. 2020;22:50.
    PubMed     Abstract available

  125. AL-ANSARI MM, Al-Saif M, Arafah M, Eldali AM, et al
    Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.
    Breast Cancer Res. 2020;22:49.
    PubMed     Abstract available

  126. REDDY TP, Choi DS, Anselme AC, Qian W, et al
    Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
    Breast Cancer Res. 2020;22:48.
    PubMed     Abstract available

  127. SKRIVER SK, Jensen MB, Knoop AS, Ejlertsen B, et al
    Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
    Breast Cancer Res. 2020;22:46.
    PubMed     Abstract available

  128. KOLBERG-LIEDTKE C, Oleg G, Fred H, Friedrich F, et al
    Association of TILs with clinical parameters, Recurrence Score(R) results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Breast Cancer Res. 2020;22:47.
    PubMed     Abstract available

  129. MARTINEZ-SAEZ O, Chic N, Pascual T, Adamo B, et al
    Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Breast Cancer Res. 2020;22:45.
    PubMed     Abstract available

  130. GALLAGHER EJ, Fei K, Feldman SM, Port E, et al
    Insulin resistance contributes to racial disparities in breast cancer prognosis in US women.
    Breast Cancer Res. 2020;22:40.
    PubMed     Abstract available

  131. SIRISENA N, Biswas K, Sullivan T, Stauffer S, et al
    Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.
    Breast Cancer Res. 2020;22:43.
    PubMed     Abstract available

  132. BURKHOLDER A, Akrobetu D, Pandiri AR, Ton K, et al
    Investigation of the adolescent female breast transcriptome and the impact of obesity.
    Breast Cancer Res. 2020;22:44.
    PubMed     Abstract available

  133. GOLE L, Yeong J, Lim JCT, Ong KH, et al
    Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients.
    Breast Cancer Res. 2020;22:42.
    PubMed     Abstract available

  134. PEREZ KERKVLIET C, Dwyer AR, Diep CH, Oakley RH, et al
    Glucocorticoid receptors are required effectors of TGFbeta1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.
    Breast Cancer Res. 2020;22:39.
    PubMed     Abstract available

    April 2020
  135. BEN HASSEN C, Gutierrez-Pajares JL, Guimaraes C, Guibon R, et al
    Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells.
    Breast Cancer Res. 2020;22:38.
    PubMed     Abstract available

  136. VAN MARCKE C, Helaers R, De Leener A, Merhi A, et al
    Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    Breast Cancer Res. 2020;22:36.
    PubMed     Abstract available

  137. MCKNIGHT BN, Kim S, Boerner JL, Viola NT, et al
    Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    Breast Cancer Res. 2020;22:37.
    PubMed     Abstract available

  138. HAIDER MT, Saito H, Zarrer J, Uzhunnumpuram K, et al
    Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment.
    Breast Cancer Res. 2020;22:34.
    PubMed     Abstract available

  139. VERNIERI C, Corti F, Nichetti F, Ligorio F, et al
    Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Breast Cancer Res. 2020;22:33.
    PubMed     Abstract available

    March 2020
  140. KIM M, Chung YR, Kim HJ, Woo JW, et al
    Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Breast Cancer Res. 2020;22:32.
    PubMed     Abstract available

  141. CHAUDHARY P, Gibbs LD, Maji S, Lewis CM, et al
    Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.
    Breast Cancer Res. 2020;22:31.
    PubMed     Abstract available

  142. QIU SQ, van Rooijen J, Nienhuis HH, van der Vegt B, et al
    High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.
    Breast Cancer Res. 2020;22:30.
    PubMed     Abstract available

  143. TANK A, Peterson HM, Pera V, Tabassum S, et al
    Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
    Breast Cancer Res. 2020;22:29.
    PubMed     Abstract available

  144. ETTL J, Im SA, Ro J, Masuda N, et al
    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
    Breast Cancer Res. 2020;22:27.
    PubMed     Abstract available

  145. ZUNDELEVICH A, Dadiani M, Kahana-Edwin S, Itay A, et al
    Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Breast Cancer Res. 2020;22:28.
    PubMed     Abstract available

  146. LI M, Pan M, You C, Zhao F, et al
    MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
    Breast Cancer Res. 2020;22:26.
    PubMed     Abstract available

    February 2020
  147. MAVADDAT N, Antoniou AC, Mooij TM, Hooning MJ, et al
    Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res. 2020;22:25.
    PubMed     Abstract available

  148. GRANT WB
    Lower vitamin D status may help explain why black women have a higher risk of invasive breast cancer than white women.
    Breast Cancer Res. 2020;22:24.

  149. LE CORNET C, Walter B, Sookthai D, Johnson TS, et al
    Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-beta, and ERbeta: results from the EPIC-Heidelberg cohort.
    Breast Cancer Res. 2020;22:23.
    PubMed     Abstract available

  150. VAKLAVAS C, Roberts BS, Varley KE, Lin NU, et al
    TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Breast Cancer Res. 2020;22:22.
    PubMed     Abstract available

  151. YANES T, Young MA, Meiser B, James PA, et al
    Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field.
    Breast Cancer Res. 2020;22:21.
    PubMed     Abstract available

  152. BODICOAT DH, Schoemaker MJ, Jones ME, McFadden E, et al
    Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.
    Breast Cancer Res. 2020;22:19.
    PubMed     Abstract available

  153. LLANOS AAM, Lin Y, Chen W, Yao S, et al
    Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype.
    Breast Cancer Res. 2020;22:18.
    PubMed     Abstract available

  154. GIARDIELLO D, Antoniou AC, Mariani L, Easton DF, et al
    Letter to the editor: a response to Ming's study on machine learning techniques for personalized breast cancer risk prediction.
    Breast Cancer Res. 2020;22:17.

  155. ZUNDELEVICH A, Dadiani M, Kahana-Edwin S, Itay A, et al
    ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Breast Cancer Res. 2020;22:16.
    PubMed     Abstract available

    January 2020
  156. PANCHOLI S, Leal MF, Ribas R, Simigdala N, et al
    Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
    Breast Cancer Res. 2020;22:14.
    PubMed     Abstract available

  157. DE RUIJTER TC, van der Heide F, Smits KM, Aarts MJ, et al
    Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
    Breast Cancer Res. 2020;22:13.
    PubMed     Abstract available

  158. OCANA A, Amir E, Pandiella A
    HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
    Breast Cancer Res. 2020;22:15.
    PubMed     Abstract available

  159. CHAUDHARY P, Gibbs LD, Maji S, Lewis CM, et al
    Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.
    Breast Cancer Res. 2020;22:11.
    PubMed     Abstract available

  160. JABER MI, Song B, Taylor C, Vaske CJ, et al
    A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Breast Cancer Res. 2020;22:12.
    PubMed     Abstract available

  161. JACOBS SA, Robidoux A, Abraham J, Perez-Garcia JM, et al
    Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
    Breast Cancer Res. 2020;22:9.
    PubMed     Abstract available

  162. WENNSTIG AK, Wadsten C, Garmo H, Fredriksson I, et al
    Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort.
    Breast Cancer Res. 2020;22:10.
    PubMed     Abstract available

  163. MAVADDAT N, Antoniou AC, Mooij TM, Hooning MJ, et al
    Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res. 2020;22:8.
    PubMed     Abstract available

  164. LEWIS K, Kiepas A, Hudson J, Senecal J, et al
    p66ShcA functions as a contextual promoter of breast cancer metastasis.
    Breast Cancer Res. 2020;22:7.
    PubMed     Abstract available

  165. HEATH AK, Muller DC, van den Brandt PA, Papadimitriou N, et al
    Nutrient-wide association study of 92 foods and nutrients and breast cancer risk.
    Breast Cancer Res. 2020;22:5.
    PubMed     Abstract available

  166. YOOSUF N, Navarro JF, Salmen F, Stahl PL, et al
    Identification and transfer of spatial transcriptomics signatures for cancer diagnosis.
    Breast Cancer Res. 2020;22:6.
    PubMed     Abstract available

  167. GOLDSTEIN LJ, Perez RP, Yardley D, Han LK, et al
    A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
    Breast Cancer Res. 2020;22:4.
    PubMed     Abstract available

  168. WANG D, Naydenov NG, Dozmorov MG, Koblinski JE, et al
    Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation.
    Breast Cancer Res. 2020;22:3.
    PubMed     Abstract available

    December 2019
  169. GAO Q, Lopez-Knowles E, Cheang MCU, Morden J, et al
    Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Breast Cancer Res. 2019;22:2.
    PubMed     Abstract available

  170. MACPHERSON IR, Spiliopoulou P, Rafii S, Saggese M, et al
    A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
    Breast Cancer Res. 2019;22:1.
    PubMed     Abstract available

  171. NEDERLOF I, De Bortoli D, Bareche Y, Nguyen B, et al
    Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
    Breast Cancer Res. 2019;21:151.
    PubMed     Abstract available

  172. FERNANDEZ-GARCIA D, Hills A, Page K, Hastings RK, et al
    Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
    Breast Cancer Res. 2019;21:149.
    PubMed     Abstract available

  173. WAN L, Liu T, Hong Z, Pan Y, et al
    NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Breast Cancer Res. 2019;21:148.
    PubMed     Abstract available

  174. SNODERLY HT, Boone BA, Bennewitz MF
    Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment.
    Breast Cancer Res. 2019;21:145.
    PubMed     Abstract available

  175. PATEL HK, Tao N, Lee KM, Huerta M, et al
    Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Breast Cancer Res. 2019;21:146.
    PubMed     Abstract available

  176. GIARDIELLO D, Steyerberg EW, Hauptmann M, Adank MA, et al
    Prediction and clinical utility of a contralateral breast cancer risk model.
    Breast Cancer Res. 2019;21:144.
    PubMed     Abstract available

  177. LI CH, Karantza V, Aktan G, Lala M, et al
    Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Breast Cancer Res. 2019;21:143.
    PubMed     Abstract available

  178. SINN BV, Weber KE, Schmitt WD, Fasching PA, et al
    Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:142.
    PubMed     Abstract available

  179. GOLDHAMMER N, Kim J, Timmermans-Wielenga V, Petersen OW, et al
    Characterization of organoid cultured human breast cancer.
    Breast Cancer Res. 2019;21:141.
    PubMed     Abstract available

  180. SHEN Q, Joud A, Schelin MEC, Sjolander A, et al
    Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skane, Sweden.
    Breast Cancer Res. 2019;21:139.
    PubMed     Abstract available

  181. PANCHOLI S, Leal MF, Ribas R, Simigdala N, et al
    Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
    Breast Cancer Res. 2019;21:135.
    PubMed     Abstract available

  182. DAVIS AA, Zhang Q, Gerratana L, Shah AN, et al
    Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Breast Cancer Res. 2019;21:137.
    PubMed     Abstract available

  183. LEE YJ, Ho SR, Graves JD, Xiao Y, et al
    CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer.
    Breast Cancer Res. 2019;21:134.
    PubMed     Abstract available

  184. JACOBS SA, Robidoux A, Abraham J, Perez-Garcia JM, et al
    NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer.
    Breast Cancer Res. 2019;21:133.
    PubMed     Abstract available

    November 2019
  185. WYATT GL, Crump LS, Young CM, Wessells VM, et al
    Cross-talk between SIM2s and NFkappaB regulates cyclooxygenase 2 expression in breast cancer.
    Breast Cancer Res. 2019;21:131.
    PubMed     Abstract available

  186. LEFLEY D, Howard F, Arshad F, Bradbury S, et al
    Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
    Breast Cancer Res. 2019;21:130.
    PubMed     Abstract available

  187. NA H, Han J, Ka NL, Lee MH, et al
    High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
    Breast Cancer Res. 2019;21:127.
    PubMed     Abstract available

  188. ZEINOMAR N, Knight JA, Genkinger JM, Phillips KA, et al
    Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).
    Breast Cancer Res. 2019;21:128.
    PubMed     Abstract available

  189. KENYON E, Westerhuis JJ, Volk M, Hix J, et al
    Ductal tree ablation by local delivery of ethanol prevents tumor formation in an aggressive mouse model of breast cancer.
    Breast Cancer Res. 2019;21:129.
    PubMed     Abstract available

  190. PUNZI S, Balestrieri C, D'Alesio C, Bossi D, et al
    WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells.
    Breast Cancer Res. 2019;21:123.
    PubMed     Abstract available

  191. DANIA V, Liu Y, Ademuyiwa F, Weber JD, et al
    Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ.
    Breast Cancer Res. 2019;21:120.
    PubMed     Abstract available

  192. JACOT W, Cottu P, Berger F, Dubot C, et al
    Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
    Breast Cancer Res. 2019;21:121.
    PubMed     Abstract available

  193. LEE JS, Yost SE, Blanchard S, Schmolze D, et al
    Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
    Breast Cancer Res. 2019;21:119.
    PubMed     Abstract available

  194. JUNG AY, Behrens S, Schmidt M, Thoene K, et al
    Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors.
    Breast Cancer Res. 2019;21:117.
    PubMed     Abstract available

    October 2019
  195. BRANDT KR, Scott CG, Miglioretti DL, Jensen MR, et al
    Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer.
    Breast Cancer Res. 2019;21:118.
    PubMed     Abstract available

  196. MORGENROTH A, Tinkir E, Vogg ATJ, Sankaranarayanan RA, et al
    Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
    Breast Cancer Res. 2019;21:116.
    PubMed     Abstract available

  197. LEE JO, Kang MJ, Byun WS, Kim SA, et al
    Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
    Breast Cancer Res. 2019;21:115.
    PubMed     Abstract available

  198. FAN M, Xia P, Liu B, Zhang L, et al
    Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients.
    Breast Cancer Res. 2019;21:112.
    PubMed     Abstract available

  199. VAN UDEN DJP, van Maaren MC, Strobbe LJA, Bult P, et al
    Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    Breast Cancer Res. 2019;21:113.
    PubMed     Abstract available

  200. PARK S, Han Y, Liu Y, Toriola AT, et al
    Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Breast Cancer Res. 2019;21:110.
    PubMed     Abstract available

    September 2019
  201. ADAMO B, Bellet M, Pare L, Pascual T, et al
    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
    Breast Cancer Res. 2019;21:108.
    PubMed     Abstract available

  202. REN J, Smid M, Iaria J, Salvatori DCF, et al
    Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression.
    Breast Cancer Res. 2019;21:109.
    PubMed     Abstract available

  203. BATALINI F, Peacock EG, Stobie L, Robertson A, et al
    Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Breast Cancer Res. 2019;21:107.
    PubMed     Abstract available

  204. LEITHNER D, Horvat JV, Marino MA, Bernard-Davila B, et al
    Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results.
    Breast Cancer Res. 2019;21:106.
    PubMed     Abstract available

  205. BARROW MA, Martin ME, Coffey A, Andrews PL, et al
    A functional role for the cancer disparity-linked genes, CRYbetaB2 and CRYbetaB2P1, in the promotion of breast cancer.
    Breast Cancer Res. 2019;21:105.
    PubMed     Abstract available

  206. MANI C, Jonnalagadda S, Lingareddy J, Awasthi S, et al
    Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Breast Cancer Res. 2019;21:104.
    PubMed     Abstract available

  207. RIEBENSAHM C, Joosse SA, Mohme M, Hanssen A, et al
    Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Breast Cancer Res. 2019;21:101.
    PubMed     Abstract available

  208. PATEL TA, Ensor JE, Creamer SL, Boone T, et al
    A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Breast Cancer Res. 2019;21:100.
    PubMed     Abstract available

    August 2019
  209. MIAO Y, Shen Q, Zhang S, Huang H, et al
    Calcium-sensing stromal interaction molecule 2 upregulates nuclear factor of activated T cells 1 and transforming growth factor-beta signaling to promote breast cancer metastasis.
    Breast Cancer Res. 2019;21:99.
    PubMed     Abstract available

  210. RAMANI VC, Lemaire CA, Triboulet M, Casey KM, et al
    Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Breast Cancer Res. 2019;21:98.
    PubMed     Abstract available

  211. DE GROOT S, Pijl H, Charehbili A, van de Ven S, et al
    Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    Breast Cancer Res. 2019;21:97.
    PubMed     Abstract available

  212. TERRY MB, Michels KB, Brody JG, Byrne C, et al
    Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research.
    Breast Cancer Res. 2019;21:96.
    PubMed     Abstract available

  213. YANG H, Pawitan Y, He W, Eriksson L, et al
    Disease trajectories and mortality among women diagnosed with breast cancer.
    Breast Cancer Res. 2019;21:95.
    PubMed     Abstract available

  214. FOERSTER M, Anderson BO, McKenzie F, Galukande M, et al
    Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study.
    Breast Cancer Res. 2019;21:93.
    PubMed     Abstract available

  215. HUANG CC, Chan SY, Lee WC, Chiang CJ, et al
    Development of a prediction model for breast cancer based on the national cancer registry in Taiwan.
    Breast Cancer Res. 2019;21:92.
    PubMed     Abstract available

  216. NAGPAL A, Redvers RP, Ling X, Ayton S, et al
    Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis.
    Breast Cancer Res. 2019;21:94.
    PubMed     Abstract available

  217. ALONZO-PROULX O, Mainprize JG, Harvey JA, Yaffe MJ, et al
    Investigating the feasibility of stratified breast cancer screening using a masking risk predictor.
    Breast Cancer Res. 2019;21:91.
    PubMed     Abstract available

  218. TAN X, Li Z, Ren S, Rezaei K, et al
    Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
    Breast Cancer Res. 2019;21:89.
    PubMed     Abstract available

  219. HORI A, Shimoda M, Naoi Y, Kagara N, et al
    Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
    Breast Cancer Res. 2019;21:88.
    PubMed     Abstract available

  220. HANCOCK BA, Chen YH, Solzak JP, Ahmad MN, et al
    Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Breast Cancer Res. 2019;21:87.
    PubMed     Abstract available

  221. KALLERGI G, Tsintari V, Sfakianakis S, Bei E, et al
    The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.
    Breast Cancer Res. 2019;21:86.
    PubMed     Abstract available

    July 2019
  222. HUSS L, Butt ST, Borgquist S, Elebro K, et al
    Vitamin D receptor expression in invasive breast tumors and breast cancer survival.
    Breast Cancer Res. 2019;21:84.
    PubMed     Abstract available

  223. KLIMOV S, Miligy IM, Gertych A, Jiang Y, et al
    A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
    Breast Cancer Res. 2019;21:83.
    PubMed     Abstract available

  224. TONSING-CARTER E, Hernandez KM, Kim CR, Harkless RV, et al
    Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Breast Cancer Res. 2019;21:82.
    PubMed     Abstract available

  225. HADA M, Oh H, Pfeiffer RM, Falk RT, et al
    Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy.
    Breast Cancer Res. 2019;21:81.
    PubMed     Abstract available

  226. BASREE MM, Shinde N, Koivisto C, Cuitino M, et al
    Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer.
    Breast Cancer Res. 2019;21:80.
    PubMed     Abstract available

  227. XING Y, Lin NU, Maurer MA, Chen H, et al
    Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Breast Cancer Res. 2019;21:78.
    PubMed     Abstract available

  228. PALOMERAS S, Diaz-Lagares A, Vinas G, Setien F, et al
    Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Breast Cancer Res. 2019;21:79.
    PubMed     Abstract available

  229. MCLAUGHLIN RP, He J, van der Noord VE, Redel J, et al
    A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    Breast Cancer Res. 2019;21:77.
    PubMed     Abstract available

    June 2019
  230. GREGORY KJ, Roberts AL, Conlon EM, Mayfield JA, et al
    Gene expression signature of atypical breast hyperplasia and regulation by SFRP1.
    Breast Cancer Res. 2019;21:76.
    PubMed     Abstract available

  231. MING C, Viassolo V, Probst-Hensch N, Chappuis PO, et al
    Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.
    Breast Cancer Res. 2019;21:75.
    PubMed     Abstract available

  232. WRIGHT KD, Miller BS, El-Meanawy S, Tsaih SW, et al
    The p52 isoform of SHC1 is a key driver of breast cancer initiation.
    Breast Cancer Res. 2019;21:74.
    PubMed     Abstract available

  233. BOWNES RJ, Turnbull AK, Martinez-Perez C, Cameron DA, et al
    On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res. 2019;21:73.
    PubMed     Abstract available

  234. RIMM DL, Han G, Taube JM, Yi ES, et al
    Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:72.
    PubMed     Abstract available

    May 2019
  235. ROSSI L, Biagioni C, McCartney A, Migliaccio I, et al
    Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
    Breast Cancer Res. 2019;21:71.
    PubMed     Abstract available

  236. LEE E, Nelson OL, Puyana C, Takita C, et al
    Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study.
    Breast Cancer Res. 2019;21:70.
    PubMed     Abstract available

  237. QUINTELA-FANDINO M, Apala JV, Malon D, Mouron S, et al
    Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
    Breast Cancer Res. 2019;21:69.
    PubMed     Abstract available

  238. VACHON CM, Scott CG, Tamimi RM, Thompson DJ, et al
    Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk.
    Breast Cancer Res. 2019;21:68.
    PubMed     Abstract available

  239. SABOL RA, Bowles AC, Cote A, Wise R, et al
    Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.
    Breast Cancer Res. 2019;21:67.
    PubMed     Abstract available

  240. FAN Y, Si W, Ji W, Wang Z, et al
    Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.
    Breast Cancer Res. 2019;21:66.
    PubMed     Abstract available

  241. BODELON C, Ambatipudi S, Dugue PA, Johansson A, et al
    Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies.
    Breast Cancer Res. 2019;21:62.
    PubMed     Abstract available

  242. JEZEQUEL P, Kerdraon O, Hondermarck H, Guerin-Charbonnel C, et al
    Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.
    Breast Cancer Res. 2019;21:65.
    PubMed     Abstract available

  243. RAMOVS V, Secades P, Song JY, Thijssen B, et al
    Absence of integrin alpha3beta1 promotes the progression of HER2-driven breast cancer in vivo.
    Breast Cancer Res. 2019;21:63.
    PubMed     Abstract available

  244. WANG Y, Zeng J, Wu W, Xie S, et al
    Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization.
    Breast Cancer Res. 2019;21:64.
    PubMed     Abstract available

  245. GRINDE MT, Hilmarsdottir B, Tunset HM, Henriksen IM, et al
    Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Breast Cancer Res. 2019;21:61.
    PubMed     Abstract available

  246. LAAKMANN E, Witzel I, Fasching PA, Rezai M, et al
    Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
    Breast Cancer Res. 2019;21:60.
    PubMed     Abstract available

  247. PROVANCE OK, Lewis-Wambi J
    Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
    Breast Cancer Res. 2019;21:59.
    PubMed     Abstract available

  248. DEMICHELI R, Dillekas H, Straume O, Biganzoli E, et al
    Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal.
    Breast Cancer Res. 2019;21:57.
    PubMed     Abstract available

    April 2019
  249. DOHERTY MR, Parvani JG, Tamagno I, Junk DJ, et al
    The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:54.
    PubMed     Abstract available

  250. WEBER-LASSALLE N, Borde J, Weber-Lassalle K, Horvath J, et al
    Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Breast Cancer Res. 2019;21:55.
    PubMed     Abstract available

  251. KEHM RD, Hopper JL, John EM, Phillips KA, et al
    Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
    Breast Cancer Res. 2019;21:52.
    PubMed     Abstract available

  252. SAMAVAT H, Xun X, Jin A, Wang R, et al
    Association between prediagnostic leukocyte telomere length and breast cancer risk: the Singapore Chinese Health Study.
    Breast Cancer Res. 2019;21:50.
    PubMed     Abstract available

  253. SHIEH Y, Scott CG, Jensen MR, Norman AD, et al
    Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
    Breast Cancer Res. 2019;21:48.
    PubMed     Abstract available

  254. BRAVACCINI S, Maltoni R
    CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
    Breast Cancer Res. 2019;21:49.

    March 2019
  255. FALSTIE-JENSEN AM, Kjaersgaard A, Lorenzen EL, Jensen JD, et al
    Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study.
    Breast Cancer Res. 2019;21:44.
    PubMed     Abstract available

  256. KENNEDY SP, Han JZR, Portman N, Nobis M, et al
    Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
    Breast Cancer Res. 2019;21:43.
    PubMed     Abstract available

  257. CLENDENEN TV, Ge W, Koenig KL, Afanasyeva Y, et al
    Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.
    Breast Cancer Res. 2019;21:42.
    PubMed     Abstract available

  258. ECKER BL, Lee JY, Sterner CJ, Solomon AC, et al
    Impact of obesity on breast cancer recurrence and minimal residual disease.
    Breast Cancer Res. 2019;21:41.
    PubMed     Abstract available

  259. FORTNER RT, Sisti J, Chai B, Collins LC, et al
    Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies.
    Breast Cancer Res. 2019;21:40.
    PubMed     Abstract available

  260. CHIA SKL, Martin M, Holmes FA, Ejlertsen B, et al
    PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Breast Cancer Res. 2019;21:39.
    PubMed     Abstract available

  261. HRUSKA CB, Hunt KN, Conners AL, Geske JR, et al
    Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.
    Breast Cancer Res. 2019;21:38.
    PubMed     Abstract available

  262. VIJAY GV, Zhao N, Den Hollander P, Toneff MJ, et al
    GSK3beta regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:37.
    PubMed     Abstract available

  263. ALZUBI MA, Turner TH, Olex AL, Sohal SS, et al
    Separation of breast cancer and organ microenvironment transcriptomes in metastases.
    Breast Cancer Res. 2019;21:36.
    PubMed     Abstract available

  264. GARCIA-ESTEVEZ L, Moreno-Bueno G
    Updating the role of obesity and cholesterol in breast cancer.
    Breast Cancer Res. 2019;21:35.
    PubMed     Abstract available

    February 2019
  265. LUNDBERG A, Lindstrom LS, Li J, Harrell JC, et al
    The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
    Breast Cancer Res. 2019;21:34.
    PubMed     Abstract available

  266. MCLEAN K, Darcey E, Cadby G, Lund H, et al
    The distribution and determinants of mammographic density measures in Western Australian aboriginal women.
    Breast Cancer Res. 2019;21:33.
    PubMed     Abstract available

  267. MORTIMER J, Di Palma J, Schmid K, Ye Y, et al
    Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Breast Cancer Res. 2019;21:32.
    PubMed     Abstract available

  268. KOLB AD, Shupp AB, Mukhopadhyay D, Marini FC, et al
    Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.
    Breast Cancer Res. 2019;21:31.
    PubMed     Abstract available

  269. KENSLER KH, Regan MM, Heng YJ, Baker GM, et al
    Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
    Breast Cancer Res. 2019;21:30.
    PubMed     Abstract available

  270. CAO W, Li J, Hao Q, Vadgama JV, et al
    AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Breast Cancer Res. 2019;21:29.
    PubMed     Abstract available

  271. VAN BERCKELAER C, Rypens C, van Dam P, Pouillon L, et al
    Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Breast Cancer Res. 2019;21:28.
    PubMed     Abstract available

  272. GREER YE, Gilbert SF, Gril B, Narwal R, et al
    MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Breast Cancer Res. 2019;21:27.
    PubMed     Abstract available

  273. EMI M, Kim R, Tanabe K, Uchida Y, et al
    Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells.
    Breast Cancer Res. 2019;21:26.
    PubMed     Abstract available

  274. NGUYEN B, Venet D, Lambertini M, Desmedt C, et al
    Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.
    Breast Cancer Res. 2019;21:25.
    PubMed     Abstract available

  275. WHITE AJ, Weinberg CR, O'Meara ES, Sandler DP, et al
    Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density.
    Breast Cancer Res. 2019;21:24.
    PubMed     Abstract available

  276. HSU YL, Yen MC, Chang WA, Tsai PH, et al
    CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.
    Breast Cancer Res. 2019;21:23.
    PubMed     Abstract available

  277. SMITH NG, Gyanchandani R, Shah OS, Gurda GT, et al
    Targeted mutation detection in breast cancer using MammaSeq.
    Breast Cancer Res. 2019;21:22.
    PubMed     Abstract available

  278. RODRIGUEZ-MARTINEZ A, de Miguel-Perez D, Ortega FG, Garcia-Puche JL, et al
    Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:21.
    PubMed     Abstract available

  279. SCHWARZENBACHER D, Klec C, Pasculli B, Cerk S, et al
    MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
    Breast Cancer Res. 2019;21:20.
    PubMed     Abstract available

    January 2019
  280. WANG DY, Gendoo DMA, Ben-David Y, Woodgett JR, et al
    A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Breast Cancer Res. 2019;21:18.
    PubMed     Abstract available

  281. GAMPENRIEDER SP, Peer A, Weismann C, Meissnitzer M, et al
    Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Breast Cancer Res. 2019;21:19.
    PubMed     Abstract available

  282. BHAT K, Sandler K, Duhachek-Muggy S, Alli C, et al
    Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
    Breast Cancer Res. 2019;21:17.
    PubMed     Abstract available

  283. XIAO Y, Xia J, Li L, Ke Y, et al
    Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.
    Breast Cancer Res. 2019;21:16.
    PubMed     Abstract available

  284. FLEMING RM, Fleming MR, Chaudhuri TK, Dooley WC, et al
    Letter to the Editor: A response to Hruska's case study on molecular breast imaging and the need for true tissue quantification.
    Breast Cancer Res. 2019;21:15.

  285. GHAFFARI A, Hoskin V, Turashvili G, Varma S, et al
    Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
    Breast Cancer Res. 2019;21:12.
    PubMed     Abstract available

  286. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2019;21:11.
    PubMed     Abstract available

  287. STRAND F, Azavedo E, Hellgren R, Humphreys K, et al
    Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study.
    Breast Cancer Res. 2019;21:8.
    PubMed     Abstract available

  288. CAMILIO KA, Wang MY, Mauseth B, Waagene S, et al
    Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Breast Cancer Res. 2019;21:9.
    PubMed     Abstract available

  289. JARMAN EJ, Ward C, Turnbull AK, Martinez-Perez C, et al
    HER2 regulates HIF-2alpha and drives an increased hypoxic response in breast cancer.
    Breast Cancer Res. 2019;21:10.
    PubMed     Abstract available

  290. LEHUEDE C, Li X, Dauvillier S, Vaysse C, et al
    Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
    Breast Cancer Res. 2019;21:7.
    PubMed     Abstract available

  291. KIJEWSKA M, Viski C, Turrell F, Fitzpatrick A, et al
    Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain.
    Breast Cancer Res. 2019;21:4.
    PubMed     Abstract available

  292. HOFFMAN J, Fejerman L, Hu D, Huntsman S, et al
    Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas.
    Breast Cancer Res. 2019;21:3.
    PubMed     Abstract available

  293. GAO C, Xiao G, Piersigilli A, Gou J, et al
    Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Breast Cancer Res. 2019;21:5.
    PubMed     Abstract available

  294. SELLI C, Turnbull AK, Pearce DA, Li A, et al
    Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
    Breast Cancer Res. 2019;21:2.
    PubMed     Abstract available

    December 2018
  295. HUDSON S, Vik Hjerkind K, Vinnicombe S, Allen S, et al
    Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk.
    Breast Cancer Res. 2018;20:156.
    PubMed     Abstract available

  296. NICKSON C, Procopio P, Velentzis LS, Carr S, et al
    Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.
    Breast Cancer Res. 2018;20:155.
    PubMed     Abstract available

  297. WU WY, Tornberg S, Elfstrom KM, Liu X, et al
    Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
    Breast Cancer Res. 2018;20:153.
    PubMed     Abstract available

  298. BHARDWAJ A, Singh H, Trinidad CM, Albarracin CT, et al
    The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
    Breast Cancer Res. 2018;20:150.
    PubMed     Abstract available

  299. BROOKS JD, Comen EA, Reiner AS, Orlow I, et al
    CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
    Breast Cancer Res. 2018;20:149.
    PubMed     Abstract available

  300. KUS K, Kij A, Zakrzewska A, Jasztal A, et al
    Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.
    Breast Cancer Res. 2018;20:148.
    PubMed     Abstract available

    November 2018
  301. MERINO VF, Cho S, Nguyen N, Sadik H, et al
    Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Breast Cancer Res. 2018;20:145.
    PubMed     Abstract available

  302. WEGE AK, Chittka D, Buchholz S, Klinkhammer-Schalke M, et al
    HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
    Breast Cancer Res. 2018;20:139.
    PubMed     Abstract available

  303. VETTER M, Landin J, Szczerba BM, Castro-Giner F, et al
    Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
    Breast Cancer Res. 2018;20:141.
    PubMed     Abstract available

  304. FRISK G, Ekberg S, Lidbrink E, Eloranta S, et al
    No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
    Breast Cancer Res. 2018;20:142.
    PubMed     Abstract available

  305. CHATTERJEE G, Pai T, Hardiman T, Avery-Kiejda K, et al
    Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.
    Breast Cancer Res. 2018;20:143.
    PubMed     Abstract available

  306. LEECH AO, Vellanki SH, Rutherford EJ, Keogh A, et al
    Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Breast Cancer Res. 2018;20:140.
    PubMed     Abstract available

  307. BECKWITT CH, Brufsky A, Oltvai ZN, Wells A, et al
    Statin drugs to reduce breast cancer recurrence and mortality.
    Breast Cancer Res. 2018;20:144.
    PubMed     Abstract available

  308. RHOST S, Hughes E, Harrison H, Rafnsdottir S, et al
    Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.
    Breast Cancer Res. 2018;20:137.
    PubMed     Abstract available

  309. VAN DER WILLIK KD, Koppelmans V, Hauptmann M, Compter A, et al
    Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.
    Breast Cancer Res. 2018;20:135.
    PubMed     Abstract available

  310. RAMIN C, May BJ, Roden RBS, Orellana MM, et al
    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
    Breast Cancer Res. 2018;20:134.
    PubMed     Abstract available

  311. SUCHANSKI J, Grzegrzolka J, Owczarek T, Pasikowski P, et al
    Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.
    Breast Cancer Res. 2018;20:133.
    PubMed     Abstract available

  312. HOPPER JL, Dite GS, MacInnis RJ, Liao Y, et al
    Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).
    Breast Cancer Res. 2018;20:132.
    PubMed     Abstract available

    October 2018
  313. MCKNIGHT BN, Viola-Villegas NT
    Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging.
    Breast Cancer Res. 2018;20:130.
    PubMed     Abstract available

  314. LIU X, Cao M, Palomares M, Wu X, et al
    Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.
    Breast Cancer Res. 2018;20:127.
    PubMed     Abstract available

    Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Breast Cancer Res. 2018;20:123.
    PubMed     Abstract available

  316. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2018;20:124.
    PubMed     Abstract available

  317. BORGEN E, Rypdal MC, Sosa MS, Renolen A, et al
    NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
    Breast Cancer Res. 2018;20:120.
    PubMed     Abstract available

  318. ANDERSEN ZJ, Jorgensen JT, Elsborg L, Lophaven SN, et al
    Long-term exposure to road traffic noise and incidence of breast cancer: a cohort study.
    Breast Cancer Res. 2018;20:119.
    PubMed     Abstract available

  319. SWERDLOW AJ, Wright LB, Schoemaker MJ, Jones ME, et al
    Maternal breast cancer risk in relation to birthweight and gestation of her offspring.
    Breast Cancer Res. 2018;20:110.
    PubMed     Abstract available

  320. UNGERLEIDER NA, Rao SG, Shahbandi A, Yee D, et al
    Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
    Breast Cancer Res. 2018;20:115.
    PubMed     Abstract available

  321. SETHURAMAN A, Brown M, Krutilina R, Wu ZH, et al
    BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion.
    Breast Cancer Res. 2018;20:117.
    PubMed     Abstract available

    September 2018
  322. YANG L, Tian Y, Leong WS, Song H, et al
    Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
    Breast Cancer Res. 2018;20:113.
    PubMed     Abstract available

  323. ABUBAKAR M, Sung H, Bcr D, Guida J, et al
    Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
    Breast Cancer Res. 2018;20:114.
    PubMed     Abstract available

  324. GAO P, Wang X, Jin Y, Hu W, et al
    Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2018;20:112.
    PubMed     Abstract available

  325. SCHOFFSKI P, Cresta S, Mayer IA, Wildiers H, et al
    A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
    Breast Cancer Res. 2018;20:109.
    PubMed     Abstract available

  326. ROSATO RR, Davila-Gonzalez D, Choi DS, Qian W, et al
    Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Breast Cancer Res. 2018;20:108.
    PubMed     Abstract available

  327. BOUSQUENAUD M, Fico F, Solinas G, Ruegg C, et al
    Obesity promotes the expansion of metastasis-initiating cells in breast cancer.
    Breast Cancer Res. 2018;20:104.
    PubMed     Abstract available

  328. LEONTOVICH AA, Jalalirad M, Salisbury JL, Mills L, et al
    NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
    Breast Cancer Res. 2018;20:105.
    PubMed     Abstract available

  329. DU T, Sikora MJ, Levine KM, Tasdemir N, et al
    Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Breast Cancer Res. 2018;20:106.
    PubMed     Abstract available

  330. BUUS R, Yeo B, Brentnall AR, Klintman M, et al
    Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
    Breast Cancer Res. 2018;20:103.
    PubMed     Abstract available

  331. WU J, Li X, Teng X, Rubin DL, et al
    Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Breast Cancer Res. 2018;20:101.
    PubMed     Abstract available

    August 2018
  332. HUTCHESON IR, Knowlden JM, Hiscox SE, Barrow D, et al
    Correction to: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Breast Cancer Res. 2018;20:98.
    PubMed     Abstract available

  333. DA CRUZ RS, Carney EJ, Clarke J, Cao H, et al
    Paternal malnutrition programs breast cancer risk and tumor metabolism in offspring.
    Breast Cancer Res. 2018;20:99.
    PubMed     Abstract available

  334. SHAIK AN, Ruterbusch JJ, Abdulfatah E, Shrestha R, et al
    Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease.
    Breast Cancer Res. 2018;20:91.
    PubMed     Abstract available

  335. ORTEGA-OLVERA C, Ulloa-Aguirre A, Angeles-Llerenas A, Mainero-Ratchelous FE, et al
    Thyroid hormones and breast cancer association according to menopausal status and body mass index.
    Breast Cancer Res. 2018;20:94.
    PubMed     Abstract available

  336. BIERMANN J, Parris TZ, Nemes S, Danielsson A, et al
    Clonal relatedness in tumour pairs of breast cancer patients.
    Breast Cancer Res. 2018;20:96.
    PubMed     Abstract available

  337. KATCHMAN BA, Tolgay Ocal I, Cunliffe HE, Chang YH, et al
    Correction to: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer.
    Breast Cancer Res. 2018;20:89.
    PubMed     Abstract available

  338. PENKERT J, Schmidt G, Hofmann W, Schubert S, et al
    Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Breast Cancer Res. 2018;20:87.
    PubMed     Abstract available

  339. LIANG X, Vacher S, Boulai A, Bernard V, et al
    Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Breast Cancer Res. 2018;20:88.
    PubMed     Abstract available

  340. SMEDA M, Kieronska A, Adamski MG, Proniewski B, et al
    Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice.
    Breast Cancer Res. 2018;20:86.
    PubMed     Abstract available

  341. POGUE BW
    Can novel technologies improve breast conserving surgery?
    Breast Cancer Res. 2018;20:85.

  342. DE ROON M, May AM, McTiernan A, Scholten RJPM, et al
    Effect of exercise and/or reduced calorie dietary interventions on breast cancer-related endogenous sex hormones in healthy postmenopausal women.
    Breast Cancer Res. 2018;20:81.
    PubMed     Abstract available

  343. DIAMOND JR, Eckhardt SG, Pitts TM, van Bokhoven A, et al
    A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
    Breast Cancer Res. 2018;20:82.
    PubMed     Abstract available

    July 2018
  344. ASANO A, Ueda S, Kuji I, Yamane T, et al
    Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2018;20:78.
    PubMed     Abstract available

  345. JENSEN MB, Laenkholm AV, Nielsen TO, Eriksen JO, et al
    The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Breast Cancer Res. 2018;20:79.
    PubMed     Abstract available

  346. LI JT, Wang LF, Zhao YL, Yang T, et al
    Retraction Note: Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis.
    Breast Cancer Res. 2018;20:77.
    PubMed     Abstract available

  347. SHINDE A, Wilmanski T, Chen H, Teegarden D, et al
    Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.
    Breast Cancer Res. 2018;20:76.
    PubMed     Abstract available

  348. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2018;20:72.
    PubMed     Abstract available

  349. O'BRIEN KM, Sandler DP, Xu Z, Kinyamu HK, et al
    Vitamin D, DNA methylation, and breast cancer.
    Breast Cancer Res. 2018;20:70.
    PubMed     Abstract available

  350. SHAPIRA M, Kakiashvili E, Rosenberg T, Hershko DD, et al
    Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
    Breast Cancer Res. 2018;20:68.
    PubMed     Abstract available

  351. SJOSTROM M, Staaf J, Eden P, Warnberg F, et al
    Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Breast Cancer Res. 2018;20:64.
    PubMed     Abstract available

  352. CHANG XZ, Li DQ, Hou YF, Wu J, et al
    Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
    Breast Cancer Res. 2018;20:63.
    PubMed     Abstract available

    June 2018
  353. DIECI MV, Tsvetkova V, Orvieto E, Piacentini F, et al
    Immune characterization of breast cancer metastases: prognostic implications.
    Breast Cancer Res. 2018;20:62.
    PubMed     Abstract available

  354. LIM KT, Cosgrave N, Hill AD, Young LS, et al
    Correction to: Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.
    Breast Cancer Res. 2018;20:61.
    PubMed     Abstract available

  355. SUROV A, Clauser P, Chang YW, Li L, et al
    Can diffusion-weighted imaging predict tumor grade and expression of Ki-67 in breast cancer? A multicenter analysis.
    Breast Cancer Res. 2018;20:58.
    PubMed     Abstract available

  356. DONZELLI S, Milano E, Pruszko M, Sacconi A, et al
    Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.
    Breast Cancer Res. 2018;20:59.
    PubMed     Abstract available

  357. ALVES CL, Elias D, Lyng MB, Bak M, et al
    SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Breast Cancer Res. 2018;20:60.
    PubMed     Abstract available

  358. ZHU Q, Tannenbaum S, Kurtzman SH, DeFusco P, et al
    Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Breast Cancer Res. 2018;20:56.
    PubMed     Abstract available

  359. SEVINSKY CJ, Khan F, Kokabee L, Darehshouri A, et al
    NDRG1 regulates neutral lipid metabolism in breast cancer cells.
    Breast Cancer Res. 2018;20:55.
    PubMed     Abstract available

  360. JIN K, Pandey NB, Popel AS
    Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Breast Cancer Res. 2018;20:54.
    PubMed     Abstract available

  361. GILES ED, Jindal S, Wellberg EA, Schedin T, et al
    Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
    Breast Cancer Res. 2018;20:50.
    PubMed     Abstract available

  362. NORTON N, Fox N, McCarl CA, Tenner KS, et al
    Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
    Breast Cancer Res. 2018;20:52.
    PubMed     Abstract available

  363. KRIKKEN E, Khlebnikov V, Zaiss M, Jibodh RA, et al
    Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res. 2018;20:51.
    PubMed     Abstract available

  364. TAWARA K, Bolin C, Koncinsky J, Kadaba S, et al
    OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
    Breast Cancer Res. 2018;20:53.
    PubMed     Abstract available

  365. LEWIS-WAMBI JS, Kim HR, Wambi C, Patel R, et al
    Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
    Breast Cancer Res. 2018;20:57.
    PubMed     Abstract available

  366. WANG C, Brentnall AR, Cuzick J, Harkness EF, et al
    Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.
    Breast Cancer Res. 2018;20:49.
    PubMed     Abstract available

  367. LARSSON AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, et al
    Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Breast Cancer Res. 2018;20:48.
    PubMed     Abstract available

  368. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2018;20:44.
    PubMed     Abstract available

  369. PAPANASTASIOU AD, Sirinian C, Kalofonos HP
    Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration.
    Breast Cancer Res. 2018;20:47.
    PubMed     Abstract available

  370. BENSEN JT, Graff M, Young KL, Sethupathy P, et al
    A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women.
    Breast Cancer Res. 2018;20:45.
    PubMed     Abstract available

  371. HRUSKA CB, Geske JR, Swanson TN, Mammel AN, et al
    Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study.
    Breast Cancer Res. 2018;20:46.
    PubMed     Abstract available

    May 2018
  372. JOHNSTON AN, Bu W, Hein S, Garcia S, et al
    Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
    Breast Cancer Res. 2018;20:42.
    PubMed     Abstract available

  373. ALLOUCHERY V, Beaussire L, Perdrix A, Sefrioui D, et al
    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Breast Cancer Res. 2018;20:40.
    PubMed     Abstract available

  374. KISH JK, Ward MA, Garofalo D, Ahmed HV, et al
    Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Breast Cancer Res. 2018;20:37.
    PubMed     Abstract available

  375. CHEN BT, Sethi SK, Jin T, Patel SK, et al
    Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study.
    Breast Cancer Res. 2018;20:38.
    PubMed     Abstract available

  376. WANDERS JOP, van Gils CH, Karssemeijer N, Holland K, et al
    The combined effect of mammographic texture and density on breast cancer risk: a cohort study.
    Breast Cancer Res. 2018;20:36.
    PubMed     Abstract available

  377. PADUA MB, Bhat-Nakshatri P, Anjanappa M, Prasad MS, et al
    Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
    Breast Cancer Res. 2018;20:35.
    PubMed     Abstract available

    April 2018
  378. HOUGHTON LC, Knight JA, De Souza MJ, Goldberg M, et al
    Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer.
    Breast Cancer Res. 2018;20:33.
    PubMed     Abstract available

  379. GOORTS B, Dreuning KMA, Houwers JB, Kooreman LFS, et al
    MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Breast Cancer Res. 2018;20:34.
    PubMed     Abstract available

  380. CAMPA D, Barrdahl M, Santoro A, Severi G, et al
    Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
    Breast Cancer Res. 2018;20:29.
    PubMed     Abstract available

  381. LIU WS, Chan SH, Chang HT, Li GC, et al
    Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
    Breast Cancer Res. 2018;20:25.
    PubMed     Abstract available

  382. WEISS A, Bashour SI, Hess K, Thompson AM, et al
    Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Breast Cancer Res. 2018;20:27.
    PubMed     Abstract available

  383. CHEN J, Wu X, Christos PJ, Formenti S, et al
    Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Breast Cancer Res. 2018;20:26.
    PubMed     Abstract available

  384. CABRERA RM, Mao SPH, Surve CR, Condeelis JS, et al
    A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration.
    Breast Cancer Res. 2018;20:24.
    PubMed     Abstract available

    March 2018
  385. TANG YC, Ho SC, Tan E, Ng AWT, et al
    Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Breast Cancer Res. 2018;20:22.
    PubMed     Abstract available

  386. EL ANSARI R, Craze ML, Miligy I, Diez-Rodriguez M, et al
    The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
    Breast Cancer Res. 2018;20:21.
    PubMed     Abstract available

  387. FROELUNDE AS, Ohlenbusch M, Hansen KB, Jessen N, et al
    Murine breast cancer feed arteries are thin-walled with reduced alpha1A-adrenoceptor expression and attenuated sympathetic vasocontraction.
    Breast Cancer Res. 2018;20:20.
    PubMed     Abstract available

  388. KNIGHT JA, Blackmore KM, Fan J, Malone KE, et al
    The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
    Breast Cancer Res. 2018;20:23.
    PubMed     Abstract available

  389. ZEIDAN B, Manousopoulou A, Garay-Baquero DJ, White CH, et al
    Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.
    Breast Cancer Res. 2018;20:19.
    PubMed     Abstract available

  390. WANG X, Huang Y, Li L, Dai H, et al
    Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis.
    Breast Cancer Res. 2018;20:18.
    PubMed     Abstract available

  391. BOYD N, Berman H, Zhu J, Martin LJ, et al
    The origins of breast cancer associated with mammographic density: a testable biological hypothesis.
    Breast Cancer Res. 2018;20:17.
    PubMed     Abstract available

  392. KIM H, Lin Q, Glazer PM, Yun Z, et al
    The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.
    Breast Cancer Res. 2018;20:16.
    PubMed     Abstract available

    February 2018
  393. SCHMIDT M, Weyer-Elberich V, Hengstler JG, Heimes AS, et al
    Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
    Breast Cancer Res. 2018;20:15.
    PubMed     Abstract available

  394. ALLOTT EH, Geradts J, Cohen SM, Khoury T, et al
    Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Breast Cancer Res. 2018;20:12.
    PubMed     Abstract available

  395. ROXANIS I, Colling R, Kartsonaki C, Green AR, et al
    The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis.
    Breast Cancer Res. 2018;20:11.
    PubMed     Abstract available

    January 2018
  396. ANNIS MG, Ouellet V, Rennhack JP, L'Esperance S, et al
    Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
    Breast Cancer Res. 2018;20:9.
    PubMed     Abstract available

  397. WEBER-LASSALLE N, Hauke J, Ramser J, Richters L, et al
    BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Breast Cancer Res. 2018;20:7.
    PubMed     Abstract available

  398. YANG H, He W, Eriksson M, Li J, et al
    Inherited factors contribute to an inverse association between preeclampsia and breast cancer.
    Breast Cancer Res. 2018;20:6.
    PubMed     Abstract available

  399. MA H, Ursin G, Xu X, Lee E, et al
    Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Breast Cancer Res. 2018;20:5.
    PubMed     Abstract available

  400. BUSBY J, Mills K, Zhang SD, Liberante FG, et al
    Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
    Breast Cancer Res. 2018;20:4.
    PubMed     Abstract available

  401. LI N, Rowley SM, Thompson ER, McInerny S, et al
    Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
    Breast Cancer Res. 2018;20:3.
    PubMed     Abstract available

  402. HUSS L, Butt ST, Almgren P, Borgquist S, et al
    SNPs related to vitamin D and breast cancer risk: a case-control study.
    Breast Cancer Res. 2018;20:1.
    PubMed     Abstract available

  403. PILLAI SG, Li S, Siddappa CM, Ellis MJ, et al
    Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Breast Cancer Res. 2018;20:2.
    PubMed     Abstract available

    December 2017
  404. THOMSEN AML, Pedersen AB, Kristensen NR, Moller BK, et al
    Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study.
    Breast Cancer Res. 2017;19:135.
    PubMed     Abstract available

  405. LI HY, Liang JL, Kuo YL, Lee HH, et al
    miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Breast Cancer Res. 2017;19:133.
    PubMed     Abstract available

  406. PARADA H JR, Sun X, Fleming JM, Williams-DeVane CR, et al
    Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.
    Breast Cancer Res. 2017;19:131.
    PubMed     Abstract available

  407. YU J, Qin B, Moyer AM, Sinnwell JP, et al
    Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Breast Cancer Res. 2017;19:130.
    PubMed     Abstract available

    November 2017
  408. HELLAND T, Henne N, Bifulco E, Naume B, et al
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Breast Cancer Res. 2017;19:125.
    PubMed     Abstract available

  409. JONES ME, Schoemaker MJ, Wright LB, Ashworth A, et al
    Smoking and risk of breast cancer in the Generations Study cohort.
    Breast Cancer Res. 2017;19:118.
    PubMed     Abstract available

  410. BAGEGNI N, Thomas S, Liu N, Luo J, et al
    Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Breast Cancer Res. 2017;19:123.
    PubMed     Abstract available

  411. HROMAS R, Kim HS, Sidhu G, Williamson E, et al
    The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Breast Cancer Res. 2017;19:122.
    PubMed     Abstract available

  412. AMANATULLAH DF, Tamaresis JS, Chu P, Bachmann MH, et al
    Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2017;19:121.
    PubMed     Abstract available

  413. OHNSTAD HO, Borgen E, Falk RS, Lien TG, et al
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Breast Cancer Res. 2017;19:120.
    PubMed     Abstract available

  414. BROUCKAERT O, Rudolph A, Laenen A, Keeman R, et al
    Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
    Breast Cancer Res. 2017;19:119.
    PubMed     Abstract available

    October 2017
  415. BERNHARDT S, Bayerlova M, Vetter M, Wachter A, et al
    Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
    Breast Cancer Res. 2017;19:112.
    PubMed     Abstract available

  416. TU CF, Wu MY, Lin YC, Kannagi R, et al
    FUT8 promotes breast cancer cell invasiveness by remodeling TGF-beta receptor core fucosylation.
    Breast Cancer Res. 2017;19:111.
    PubMed     Abstract available

    September 2017
  417. PELEKANOU V, Carvajal-Hausdorf DE, Altan M, Wasserman B, et al
    Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Breast Cancer Res. 2017;19:109.

    May 2017
  418. BRAMAN NM, Etesami M, Prasanna P, Dubchuk C, et al
    Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Breast Cancer Res. 2017;19:57.
    PubMed     Abstract available

  419. SAMENI M, Cavallo-Medved D, Franco OE, Chalasani A, et al
    Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
    Breast Cancer Res. 2017;19:56.
    PubMed     Abstract available

    March 2017
  420. ELSHOF LE, Schaapveld M, Rutgers EJ, Schmidt MK, et al
    The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Breast Cancer Res. 2017;19:26.
    PubMed     Abstract available

  421. UBELLACKER JM, Haider MT, DeCristo MJ, Allocca G, et al
    Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Breast Cancer Res. 2017;19:23.
    PubMed     Abstract available

    February 2017
  422. SCHOEMAKER MJ, Jones ME, Allen S, Hoare J, et al
    Childhood body size and pubertal timing in relation to adult mammographic density phenotype.
    Breast Cancer Res. 2017;19:13.
    PubMed     Abstract available

  423. TER BRAAK B, Siezen CL, Lee JS, Rao P, et al
    Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production.
    Breast Cancer Res. 2017;19:14.
    PubMed     Abstract available

    January 2017
  424. BARCUS CE, O'Leary KA, Brockman JL, Rugowski DE, et al
    Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
    Breast Cancer Res. 2017;19:9.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.